{"id":7269,"date":"2025-05-21T18:06:27","date_gmt":"2025-05-21T18:06:27","guid":{"rendered":"https:\/\/stoxpo.com\/?p=7269"},"modified":"2025-05-21T18:06:28","modified_gmt":"2025-05-21T18:06:28","slug":"telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/05\/21\/telomir-pharmaceuticals-secures-3m-premium-equity-investment-to-advance-rare-disease-program\/","title":{"rendered":"Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program"},"content":{"rendered":"\n

Insider-Led Funding with No Warrants Strengthens Balance Sheet Ahead of IND Submission for Telomir-1<\/h4>\n\n\n\n

Telomir Pharmaceuticals (TELO), a biotech innovator focused on age-reversal science, announced a $3 million equity investment from its largest shareholder, The Bayshore Trust. The deal was structured as a straight equity sale\u20141 million restricted shares at $3.00 per share\u2014representing an 18% premium to Telomir\u2019s closing stock price of $2.54 at the time of execution.<\/p>\n\n\n\n

Importantly, the financing includes no warrants, no discounts, and no convertible features, signaling strong insider conviction and a commitment to shareholder-friendly terms.<\/p>\n\n\n\n

This follows a previous $1 million investment at $7.00 per share in December 2024 from The Starwood Trust, an entity affiliated with the same shareholder group. Telomir also maintains access to a $5 million undrawn, non-dilutive line of credit from the same affiliate, bringing its total insider-backed funding potential to $9 million.<\/p>\n\n\n\n

\u201cWe\u2019ve now raised $4 million in equity and secured an additional $5 million in non-dilutive capital\u2014all without toxic structures,\u201d said Erez Aminov, Chairman and CEO of Telomir. \u201cThis capital will directly support the IND submission for Telomir-1 and early clinical work in a rare disease setting.\u201d<\/p>\n\n\n\n

Telomir-1, the company\u2019s lead candidate, is a first-in-class small molecule designed to reverse cellular aging by targeting five core biological processes, including mitochondrial dysfunction and telomere shortening.<\/p>\n\n\n\n

In parallel, the company is developing Telomir-Ag2, a stabilized Silver(II) compound aimed at combating drug-resistant infections.<\/p>\n\n\n\n

With a focus on long-term value creation and disciplined capital management, Telomir\u2019s recent raise positions it well to pursue regulatory milestones and clinical progress in the months ahead.<\/p>\n\n\n\n

You might like this article:Elon Musk Confirms Tesla and xAI to Continue Buying AI Chips from Nvidia and AMD<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Insider-Led Funding with No Warrants Strengthens Balance Sheet Ahead of IND Submission for Telomir-1 Telomir Pharmaceuticals (TELO), a biotech innovator focused on age-reversal science, announced a $3 million equity investment from its largest shareholder, The Bayshore Trust. The deal was structured as a straight equity sale\u20141 million restricted shares at $3.00 per share\u2014representing an 18% […]<\/p>\n","protected":false},"author":2,"featured_media":5518,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[309,359],"tags":[421,416,418,417],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7269"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=7269"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7269\/revisions"}],"predecessor-version":[{"id":7270,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7269\/revisions\/7270"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/5518"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=7269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=7269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=7269"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=7269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}